lamivudine has been researched along with dolutegravir in 228 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 94 (41.23) | 24.3611 |
| 2020's | 134 (58.77) | 2.80 |
| Authors | Studies |
|---|---|
| Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F | 1 |
| Antela, A; Clumeck, N; Duiculescu, D; Eberhard, A; Granier, C; Gutiérrez, F; Hocqueloux, L; Maggiolo, F; Min, S; Nichols, G; Pappa, K; Sandkovsky, U; Walmsley, SL; Wynne, B | 1 |
| Abraham, T; Saad, N; Wu, G | 1 |
| Barreiro, P; De Mendoza, C; Fernandez-Montero, JV; Labarga, P; Soriano, V | 1 |
| Borland, J; Chen, S; Piscitelli, SC; Savina, P; Weller, S; Wynne, B | 1 |
| Chen, S; Letendre, SL; Mills, AM; Min, SS; Piscitelli, SC; Song, IH; Tashima, KT; Thomas, DA | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Mesplède, T; Singhroy, DN; Wainberg, MA | 1 |
| A Rostad, C; Anderson, EJ; Camacho-Gonzalez, AF; Chakraborty, R; O Akerele, D; Spearman, P; Thompson, AB; Wynn, BA | 1 |
| Deeks, ED; Greig, SL | 1 |
| Domingo, P; Rivero, A | 1 |
| Bollen, P; Burger, D; Reiss, P; Schapiro, J | 1 |
| Baumgarten, A; Berenguer, J; Felizarta, F; Florence, E; Granier, C; Khuong-Josses, MA; Kilby, JM; Lutz, T; Pappa, K; Podzamczer, D; Portilla, J; Roth, N; Walmsley, S; Wong, D; Wynne, B | 1 |
| Bailly, F; Cotelle, P | 1 |
| Freedberg, KA; Girouard, MP; Gulick, RM; Paltiel, AD; Parker, RA; Sax, PE; Taiwo, B; Walensky, RP; Weinstein, MC | 1 |
| Desai, A; Kadam, N; Raotole, N; Samanta, G; Tol, T | 1 |
| Baldin, G; Borghetti, A; Cauda, R; Ciccarelli, N; Ciccullo, A; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Fanti, I; Gagliardini, R; Lamonica, S; Mondi, A; Trecarichi, E | 1 |
| Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F | 1 |
| Andany, N; Gold, WL | 1 |
| Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W | 1 |
| Emerson, CR; Todd, S | 1 |
| Acerete, L; Curto, J; Ferrer, E; Imaz, A; Kashuba, AD; Martinez-Picado, J; Niubó, J; Ouchi, D; Podzamczer, D; Rozas, N; Sykes, C; Vila, A | 1 |
| Comi, L; Maggiolo, F | 1 |
| Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N | 1 |
| Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A | 1 |
| Bhattarai, S; Fallon, JP; Galang, H; Habeeb, R; Johnson, TM; Shukla, PP; Sison, R; Slim, J | 1 |
| Akkina, R; Akkina, SR; Habu, Y; Hu, S; Kumar, DM; Neff, CP; Seki, T | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Echeverría, P; Estany, C; Estrada, V; Gutiérrez, MD; Mateo, GM; Negredo, E; Ornelas, A; Puig, J; Toro, J | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Benatti, S; Callegaro, A; Digaetano, M; Gulminetti, R; Maggiolo, F; Mussini, C; Pagnucco, L; Ripamonti, D; Valenti, D | 1 |
| Aboud, M; Brennan, C; Brinson, C; Granier, C; Hopking, J; Koteff, JA; Lake, JE; Logue, K; Santiago, L; Trottier, B; Wynne, B | 1 |
| Cahn, P; Figueroa, MI; Gun, A; Patterson, P; Rolón, MJ; Sued, O | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; Llibre, JM; Margusino-Framiñán, L; Martín-Herranz, I; Pernas-Souto, B; Poveda, E | 1 |
| Aboud, M; Aylott, A; Belonosova, E; Buchanan, AM; Falcó, V; Hagins, DP; Man, CY; Orrell, C; Porteiro, N; Smith, KY; Vavro, C; Walmsley, S; Wynne, B | 1 |
| Aubin, C; Cawston, H; Finkielsztejn, L; Guilmet, C; Laurisse, A; Marcelin, AG; Pialoux, G | 1 |
| de Boer, M; Hovens, J; Scheper, H; van Holten, N | 1 |
| Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL | 1 |
| Berenguer Berenguer, J; Cenoz Gomis, S; Graefenhain, R; Lopez Sanchez-Cambronero, D; Losa García, JE; Martínez Sesmero, JM; Moreno Guillen, S; Parrondo Garcia, FJ | 1 |
| Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D | 1 |
| Baker, D; Bloch, M; Brown, D; Drummond, F; Ferrer, PE; Finlayson, R; Koh, K; Orth, D; Roth, N; Urbaityte, R | 1 |
| Charpentier, C; Meftah, N; Montes, B; Perrier, M; Reynes, J | 1 |
| Bossacoma Busquets, F; Fortuny, C; Noguera-Julian, A; Sanchez, E | 1 |
| Acosta, E; Bezins, B; Godfrey, C; Gulick, RM; Haas, D; Nyaku, A; Sax, PE; Sha, B; Smith, KY; Stefanescu, A; Taiwo, BO; Van Dam, C; Wallis, CL; Zheng, L | 1 |
| Acosta, EP; Benson, CA; Berzins, B; Colasanti, J; Fichtenbaum, CJ; Koletar, SL; Li, JZ; Marconi, VC; Moser, CB; Nyaku, AN; Sax, PE; Taiwo, BO; Wilkin, T | 1 |
| Campbell, S; Gill, MJ; Gill, VC; Krentz, HB | 1 |
| Boswell, R; Foisy, MM; Hughes, CA | 1 |
| Blanco, JL; Casadella, M; Clotet, B; de Lazzari, E; Gatell, JM; Mallolas, J; Martinez, E; Negredo, E; Paredes, R; Rojas, J | 1 |
| Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Chen, TC; Chuang, ZM | 1 |
| Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
| Iavarone, M; Maggioni, M; Merli, M; Orcese, C; Puoti, M; Rossotti, R | 1 |
| Chmelík, V; Chrdle, A; Jerhotová, Z; Linka, M; Vacík, M | 1 |
| Buchanan, AM; Casillas, L; Joshi, S; Shaik, JSB; Shreeves, T; Singh, RP; Skoura, N | 1 |
| Baldin, G; Capetti, A; Ciccullo, A; Colafigli, M; Cossu, MV; d'Ettorre, G; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Modica, S; Restelli, S; Rusconi, S; Sterrantino, G | 1 |
| Bukin, EK; Chounta, V; Garib, SA; Holbrook, T; Piercy, J; Punekar, YS; Tremblay, G | 1 |
| De la Torre, J; Del Arco, A; García de Lomas, JM; García-Alegría, J; Márquez, E; Nieto, M; Olalla, J; Pérez-Stachowski, J; Prada, JL; Tortajada, B | 1 |
| Carelli, M; Chiesi, S; Diani, E; Gibellini, D; Lanzafame, M; Lattuada, E; Nicole, S; Piacentini, D; Rizzardo, S; Vento, S | 1 |
| Badowski, ME; Michienzi, SM; Schriever, CA | 1 |
| Benson, CA; Berzins, B; Deng, Q; Fichtenbaum, CJ; Gianella, S; Marconi, VC; Moser, C; Oliveira, MF; Sax, P; Taiwo, BO; Vargas, M; Wilkin, T | 1 |
| Eberle, J; Kroidl, A | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Cahn, P; Clarke, AE; Currie, A; Fettiplace, A; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, C; Ortiz, R; Pappa, K; Rockstroh, JK; Sievers, J; Smith, K; Tenorio, AR; Underwood, M; Wynne, B | 1 |
| Baptiste, SL; Etya'ale, HM; Taro, TB | 1 |
| Amri, I; Argoud, AL; Benalycherif, A; Burdet, C; Cabié, A; Charpentier, C; Descamps, D; Joly, V; Katlama, C; Landman, R; Mentre, F; Peytavin, G; Vigan, M; Yazdanpanah, Y; Yeni, P | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; D'Avino, A; Di Giambenedetto, S; Dusina, A; Emiliozzi, A; Gagliardini, R; Lassandro, AP; Lombardi, F; Moschese, D | 1 |
| Allavena, C; André-Garnier, E; Billaud, E; Grégoire, M; Guimard, T; Hall, N; Jovelin, T; Khatchatourian, L; Le Guen, L; Morrier, M; Perré, P; Raffi, F; Reliquet, V; Rodallec, A; Volteau, C | 1 |
| Rijnders, BJA; Rokx, C | 1 |
| Allavena, C; André, M; Avettand-Fènoël, V; Bernard, L; Billaud, E; Esnault, JL; Hocqueloux, L; Le Moal, G; Parienti, JJ; Prazuck, T; Raffi, F; Rey, D; Roncato-Saberan, M; Sunder, S; Valéry, A | 1 |
| Fujiwara, T; Kawauchi-Miki, S; Miki, S; Seki, T; Yoshinaga, T | 1 |
| Heldwein, S; Jaeger, H; Noe, S; Page, M; Wolf, E | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Acosta, EP; Berzins, B; Godfrey, C; Gulick, RM; Haas, DW; Nyaku, AN; Olefsky, M; Sax, PE; Sha, BE; Smith, KY; Taiwo, BO; Van Dam, CN; Wallis, CL; Zheng, L | 1 |
| Capetti, A; Cattaneo, D; Rizzardini, G | 1 |
| Baldin, G; Borghetti, A; Ciccullo, A; Di Giambenedetto, S | 2 |
| Aboud, M; Bedimo, R; Berzins, B; Gillman, J; Gulick, R; Janulis, P; Smith, K; Taiwo, B; Wallis, CL | 1 |
| Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y | 1 |
| Barber, TJ | 1 |
| Halquist, MS; Hauser, KF; Jones, AM; Kashuba, ADM; Kim, WK; Knapp, PE; Leibrand, CR; Masuda, QN; McRae, M; Paris, JJ | 1 |
| Fida, M; Rizza, SA; Temesgen, Z | 1 |
| Ferrante, S; Parks, DC; Punekar, Y; Radford, M | 1 |
| Al-Chalabi, A; Garcia Montojo, M; Gold, J; Kiernan, MC; Lombardi, V; Malaspina, A; Mathers, S; Mehta, PR; Nath, A; Norato, G; Rogers, ML; Rowe, DB; Santamaria, UA; van den Berg, LH; van Eijk, RPA; Vucic, S; Westeneng, HJ | 1 |
| Gompels, M; Johnston, S; Nicholls, J; Tan, M | 1 |
| Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
| Katzenstein, D; Kouamou, V; Makadzange, AT; Manasa, J; McGregor, AM; Ndhlovu, CE | 1 |
| Cortés, LL; Fernández, E; Gálvez, C; García, C; Gutiérrez, A; Hidalgo-Tenorio, C; Jesús, SE; Omar, M; Pasquau, J; Santos, J; Sequera, S; Téllez, F | 1 |
| Cento, V; Perno, CF | 1 |
| Baldin, G; Borghetti, A; Capetti, A; Ciccullo, A; Cossu, MV; Di Giambenedetto, S; Passerini, M | 1 |
| Alves Saldanha, S; Battegay, M; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M | 1 |
| Adkison, K; Boffito, M; Cahn, P; Demarest, J; Koteff, J; Paredes, R; Quercia, R; Van Wyk, J; Vincent, T; Waters, L | 1 |
| Badowski, ME; Brizzi, MB; Chiampas, TD; Michienzi, SM; Patel, MC; Young, JD | 1 |
| Borghi, V; Di Giambenedetto, S; Francisci, D; Franzetti, M; Giacomelli, A; Lai, A; Lepore, L; Lombardi, F; Maggiolo, F; Magnani, G; Monno, L; Paolucci, S; Pecorari, M; Rusconi, S; Vicenti, I | 1 |
| Saag, MS | 1 |
| Arcara, A; Benfield, M; Brown, J; Crump, LH; Mospan, C; Mospan, G; Ramey, C; Yang, S | 1 |
| Duarte, F; Soares, MA | 1 |
| Adkison, K; Bakshi, K; Dumitrescu, TP; Fu, C; Joshi, S; Peddiraju, K; Spancake, C; Tenorio, AR; Wolstenholme, A; Yu, S; Zhang, Z | 1 |
| Agulló, V; Fernández-González, M; García, JA; García-Abellán, J; Gutiérrez, F; Masiá, M; Padilla, S | 1 |
| Baldin, G; Borghetti, A; Borghi, V; Brescini, L; Capetti, A; Celani, L; Ciccullo, A; Colafigli, M; Cossu, MV; Di Giambenedetto, S; Dusina, A; Gennari, W; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Mussini, C; Restelli, S; Rossetti, B; Rusconi, S; Sterrantino, G; Vignale, F | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Brandon, DJ; Cahn, P; Clarke, AE; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, CY; Ortiz, R; Pappa, KA; Rockstroh, JK; Sievers, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; van Wyk, J; Wynne, B | 1 |
| Baldin, G; Capetti, A; Celani, L; Ciccullo, A; Cossu, MV; Di Giambenedetto, S; Freedman, A; Giacomelli, A; Giacometti, A; Lagi, F; Latini, A; Madeddu, G; Rossetti, B; Rusconi, S; Sterrantino, G | 1 |
| Scott, LJ | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Godfrey, C; Gulick, R; Ha, B; Kumwenda, J; Nyaku, AN; Olefsky, M; Quiñones-Mateu, ME; Sax, PE; Smith, K; Taiwo, BO; Wallis, C; Zheng, L | 1 |
| Bossolasco, S; Castagna, A; Cinque, P; Dell'Acqua, R; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Mastrangelo, A; Muccini, C; Poli, A | 1 |
| Baldin, G; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Lombardi, F | 1 |
| Lodi, VJC; Monteiro, JCMS; Pires, CAA; Rego, RM | 1 |
| Aboud, M; Baril, JG; Bogner, J; Eron, J; Falcó, V; Gartland, M; Hung, CC; Koteff, J; Maggiolo, F; Man, CY; Mills, A; Pappa, KA; Sievers, J; Slim, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; Wynne, B | 1 |
| Azran, C; Dahan, A; Elazary, R; Elinav, H; Gibori, R; Horwitz, E; Israel, S; Porat, D | 1 |
| Davis, CC; Hassounah, S; Heredia, A; Kashanchi, F; Le, NM; Medina-Moreno, S; Mesplede, T; Oliveira, M; Zapata, JC | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Jary, A; Lê, MP; Marcelin, AG; Peytavin, G; Wirden, M | 1 |
| Benalycherif, A; Burdet, C; Cabie, A; Charpentier, C; Collin, G; Descamps, D; Joly, V; Katlama, C; Landman, R; Lê, MP; Mentré, F; Peytavin, G; Raffi, F; Yazdanpanah, Y | 1 |
| Belmonti, S; Borghetti, A; Cauda, R; di Giambenedetto, S; Fabbiani, M; Lombardi, F; Marchetti, S; Tamburrini, E | 1 |
| Baldin, G; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Dusina, A; Lassandro, AP | 1 |
| Abrams, EJ; Bartilol, K; Batuka, J; Gitonga, M; Imbuki, E; Kimani, M; Lahuerta, M; Odhiambo, J; Odhiambo, S; Sugandhi, N; Syowai, M; Vakil, S; Wamicwe, J | 1 |
| Blackman, AL; Devanathan, AS; Heil, EL; Pandit, NS | 1 |
| Alejos, B; Aranguren-Rivas, P; Arribas, JR; Bermejo-Plaza, L; Bisbal, O; Cadiñanos, J; Castro, JM; De Miguel, R; Delgado, R; Dominguez-Dominguez, L; Esteban-Cantos, A; Garcia-Alvarez, M; Hernando, A; Martin-Carbonero, L; Mayoral, M; Montejano, R; Moreno, V; Pulido, F; Rial-Crestelo, D; Rubio, R; Santacreu-Guerrero, M; Stella-Ascariz, N | 1 |
| Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D | 1 |
| Conti, F; Giacomelli, A; Rusconi, S | 1 |
| Childs-Kean, LM; Miller, S; Santevecchi, BA | 1 |
| Fida, M; Mahmood, M; Temesgen, Z | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Arrieta-Aldea, I; Brown, TT; Bujosa, D; Díez-Pérez, A; García-Giralt, N; González-Mena, A; Güerri-Fernández, R; Knobel, H; Lerma-Chippirraz, E; Pineda-Moncusi, M; Soldado-Folgado, J; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Granozzi, B; Re, MC; Testi, D; Viale, P | 1 |
| Alhassan, Y; Kambugu, A; Khoo, S; Lamorde, M; Malaba, T; Myer, L; Orrell, C; Reynolds, H; Taegtmeyer, M; Twimukye, A; Waitt, C | 1 |
| Axe, D; Ivos, M; Morris, JE | 1 |
| Arribas, JR; Battegay, M; Béguelin, C; Bhagani, S; Cinque, P; Collins, S; Cotter, A; De Miguel, R; Guaraldi, G; Kirk, O; Kowalska, JD; Mallon, P; Marzolini, C; Molina, JM; Podlekareva, D; Rauch, A; Ryom, L; Winston, A | 1 |
| Belmonti, S; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L | 1 |
| Blennow, K; Fuchs, D; Gisslén, M; Gostner, J; Martinez, E; Navarro-Alcaraz, A; Niubo, J; Piatti, C; Podzamczer, D; Rigo-Bonnin, R; Rojas, J; Tiraboschi, JM; Zetterberg, H | 1 |
| Alejos, B; Aranguren-Rivas, P; Arribas, JR; Bermejo-Plaza, L; Bisbal, O; Cadiñanos, J; Castro, JM; de Miguel, R; Delgado, R; Dominguez-Dominguez, L; Esteban-Cantos, A; Garcia-Alvarez, M; Hernando, A; Martin-Carbonero, L; Mayoral, M; Montejano, R; Moreno, V; Pulido, F; Rial-Crestelo, D; Rubio, R; Santacreu-Guerrero, M | 1 |
| Hamzah, L; Post, FA | 1 |
| Be, G; Cattaneo, P; Gottardo, R; Lanzafame, M; Lattuada, E; Luise, D; Piacentini, D; Razzaboni, E; Vento, S | 1 |
| Baldin, G; Borghi, V; Ciccullo, A; Di Giambenedetto, S; Farinacci, D; Guaraldi, G; Lassandro, AP; Mussini, C | 1 |
| Ait-Khaled, M; Ajana, F; Jones, B; Nascimento, MC; Santos, J; Scholten, S; Smith, DE; Tenorio, AR; van Wyk, J; Wohlfeiler, M; Wright, J; Wynne, B | 1 |
| Cassidy, T; Flowers, T; Gcwabe, Z; Goemaere, E; Goliath, R; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Sayed, K; Schutz, C; Simmons, B; van Zyl, G; Wiesner, L; Zhao, Y | 1 |
| Kulkarni, SS; Mullick, P; Mutalik, S; Mutalik, SP; Pandey, A | 1 |
| Angelis, K; Berhe, M; Dalessandro, M; Leone, PA; Matthews, JE; Merrill, D; Nguyen, C; Ortiz, R; Ramgopal, M; Rolle, CP; Singh, T; Underwood, MR; van Wyk, J; Wurapa, A; Wynne, BR; Zolopa, AR | 1 |
| Bonazzetti, C; Conti, F; Formenti, T; Galli, M; Giacomelli, A; Morena, V; Oreni, L; Pagani, G; Pezzati, L; Ridolfo, AL; Rusconi, S | 1 |
| Marukutira, T; Wood, BR | 1 |
| Alejos, B; Bernal, E; de Zárraga Fernández, MA; García Yubero, C; Jarrín, I; Moreno, C; Pérez-Is, L; Ruiz-Algueró, M; Samperiz Abad, G; Suárez-García, I; Zubero, Z | 1 |
| Lázaro, A; Mendoza, I; Torralba, M | 1 |
| Lu, H; Sun, J | 1 |
| Abdulghani, N; Blanco, JL; Clotet, B; de Lazzari, E; Domingo, P; Gatell, JM; Gutierrez, MM; Martínez, E; Mateo, MG; Negredo, E; Paredes, R; Podzamczer, D; Puig, J; Ribera, E; Rojas, J; Tiraboschi, J | 1 |
| Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Cossu, MV; d'Ettorre, G; De Vito, A; Di Giambenedetto, S; Gennari, W; Giacomelli, A; Giacometti, A; Latini, A; Madeddu, G; Mussini, C; Rusconi, S; Sterrantino, G | 1 |
| Abdelzaher, AM; Elmaaty, AA; Hasan, MA; Serag, A; Tolba, EH | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Brandon, DJ; Cahn, P; Clarke, AE; Curtis, L; Gartland, M; Girard, PM; Hung, CC; Man, CY; Ortiz, R; Pappa, KA; Rockstroh, JK; Sierra Madero, J; Sievers, J; Smith, KY; Underwood, M; Urbaityte, R; van Wyk, J; Wynne, B | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Oliveira, C; Giménez-Arufe, V; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Martínez-Pradeda, A; Mena-De-Cea, Á; Míguez-Rey, E; Rotea-Salvo, S; Vázquez-Rodríguez, P | 1 |
| Allavena, C; Bani-Sadr, F; Cabie, A; Cuzin, L; Deschanvres, C; Duvivier, C; Hocqueloux, L; Joly, V; Lamaury, I; Palich, R; Raffi, F; Rey, D; Reynes, J; Robineau, O | 1 |
| Bon, I; Calza, L; Fulgaro, C; Lazzarotto, T; Legnani, G; Verucchi, G; Viale, P | 1 |
| Adkison, KK; Baker, M; Brothers, C; Buchanan, AM; Davies, M; Parasrampuria, R; Sewell, N; Singh, RP; Wolstenholme, A | 1 |
| Alkhatib, M; Borghetti, A; Borghi, V; Di Giambenedetto, S; Duca, L; Dusina, A; Zazzi, M | 1 |
| Dodda, S; Gangarapu, K; Veerareddy, V | 1 |
| Barbini, B; Campbell, L; Fox, J; Gilleece, Y; Ibrahim, F; Orkin, C; Post, FA; Samarawickrama, A; Tariq, S; Waters, L | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Bowen, N; Inzaule, SC; Jordan, MR; Kiiru, JN; Kingwara, L; Momanyi, L; Ngugi, C; Nyanya, W; Oramisi, V | 1 |
| Chen, P; Deng, L; Hong, Z; Li, C; Luo, X; Xia, J; Zheng, X; Zhou, L; Zhou, Y | 1 |
| Christensen, BL; Tan, DH | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Baccini, M; Borghetti, A; Borghi, V; Callegaro, A; Dreassi, E; Gagliardini, R; Lodi, MA; Lombardi, F; Micheli, V; Modica, S; Montagnani, F; Pecorari, M; Rossetti, B; Zanelli, G; Zazzi, M | 1 |
| Blair, E; Bontempo, G; Brites, C; Cheng, CY; Curtis, L; Degen, O; Galera, C; Hocqueloux, L; Llibre, JM; Maggiolo, F; Man, C; Osiyemi, O; Oyee, J; Taylor, S; Underwood, M; van Wyk, J; Wynne, B | 1 |
| de la Mora, L; García, F; Llibre, JM; Noguera-Julián, M; Paredes, R; Parera, M; Revollo, B; Viñuela, L | 1 |
| Blanco, JR; de la Torre-Lima, J; Ferra, S; García-Vallecillos, C; Hidalgo-Tenorio, C; López-Lirola, A; López-Ruz, MÁ; Martínez, OJ; Montero, M; Omar, M; Palomares, J; Pasquau, J; Payeras, A; SanJoaquín, I; Terrón, A; Vinuesa, D | 1 |
| Ake, JA; Bahemana, E; Chang, D; Crowell, TA; Dear, NF; Esber, AL; Iroezindu, M; Kibuuka, H; Maswai, J; Owuoth, J; Polyak, CS; Singoei, V | 1 |
| Blanco, JR; Calzado Isbert, S; López Cortés, LF; Martínez-Sanz, J; Mena, Á; Moreno, E; Moreno, S; Muriel, A; Pineda, JA; Ron, R; Sánchez-Conde, M; Serrano-Villar, S | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Gan, X; Hui, X; Li, Q; Sun, W | 1 |
| Ackley, C; Clarke, A; Fray, D; Garcia Rodriguez, D; Villa, G | 1 |
| Amstutz, A; Belus, JM; Brown, JA; Glass, TR; Klimkait, T; Labhardt, ND; Mokhele, K; Muhairwe, J; Nsakala, BL; Rakuoane, I; Tschumi, N | 1 |
| Evans, D; Hans, L; Levin, L; Steegen, K; Technau, KG | 1 |
| Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D | 1 |
| Abdi, B; Bitilinyu-Bangoh, JE; Calvez, V; Descamps, D; Jahn, A; Kalua, T; Lê, MP; Marcelin, AG; Nicholas, S; Ousley, J; Peytavin, G; Schramm, B; Storto, A; Szumilin, E; Temfack, E | 1 |
| Allard, SD; Ausselet, N; Darcis, G; De Scheerder, MA; De Wit, S; Delforge, M; Demeester, R; Florence, E; Henrard, S; Loeckx, M; Messiaen, P; Nasreddine, R; Yombi, JC | 1 |
| Katzenstein, D; Kouamou, V; Machekano, R; Manasa, J; Mapangisana, T; Maposhere, C; McCarty, K; Munyati, S; Mutsvangwa, J; Shamu, T | 1 |
| Cai, K; Chen, W; He, Y; Liu, X; Rao, M; Sun, L; Wang, H; Xu, L; Zhang, L; Zhao, F | 1 |
| Cai, L; Guo, Z; He, S; Wang, Y; Wang, Z; Yan, D; Yang, X; Zheng, Y | 1 |
| Chen, C; Hu, Y; Huang, J; Lv, R; Ma, P; Pei, X; Qi, M; Su, Y; Wei, H; Yan, L; Ye, Z; Zhong, M; Zou, M | 1 |
| Fu, Y; Gan, L; Li, J; Long, H; Song, C; Song, Y; Xie, X; Yang, X | 1 |
| Callegaro, A; Cervo, A; Digaetano, M; Gulminetti, R; Maggiolo, F; Mussini, C; Pagnucco, L; Valenti, D | 1 |
| Antinori, S; Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Cossu, MV; Di Giambenedetto, S; Farinacci, D; Giacomelli, A; Iannone, V; Lagi, F; Mussini, C; Passerotto, RA; Sterrantino, G | 1 |
| Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H | 1 |
| Burger, DM; Fraaij, PLA; Gruters, RA; Lungu, C; Mahmud, R; Mesplède, T; Overmars, RJ; Pham, HT; Rokx, C; Schurink, CAM; van Boheemen, S; van de Vijver, DAMC; van Kampen, JJA; Voermans, JJC; Yoo, S | 1 |
| Bendala-Estrada, AD; Bernardino, JI; Busca, C; Cadiñanos, J; Delgado-Hierro, A; Diaz-Almiron, M; Martin-Carbonero, L; Mican, R; Montejano, R; Montes, ML; Valencia, E | 1 |
| Antinori, A; Borghi, V; Castagna, A; Cozzi-Lepri, A; Gagliardini, R; Galli, L; Lorenzini, P; Maggiolo, F; Monforte, AD; Mussini, C; Tagliaferri, G; Tavelli, A | 1 |
| Cabello-Ubeda, A; de Quirós, JCLB; Górgolas, M; Gutiérrez, Á; Hernández Segurado, M; Martín Carbonero, L; Mena, Á; Palmier, E; Pinto, A; Pulido, F; Sanz, J; Tejerina, F; Torralba, M; Vázquez, P; Vergas, J | 1 |
| Ahn, JY; Choi, JY; Jeong, SJ; Kim, CH; Kim, J; Kim, JH; Ku, NS; Lee, JA; Lee, KH; Song, YG; Yeom, JS | 1 |
| Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF | 1 |
| Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y | 1 |
| Aristegui, I; Cahn, P; Cardozo, N; Cesar, C; Figueroa, MI; Fink, V; Frola, CE; Gun, A; Patterson, P; Radusky, PD; Sued, O; Zalazar, V | 1 |
| Abba, A; Beloumou, GA; Billong, SC; Bouba, NP; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa Ndjeyep, SC; Eben-Moussi, E; Etame, NK; Fokam, J; Ka'e, AC; Kengni, AMN; Kouanfack, C; Meledie, AP; Molimbou, E; Mossiang, L; Ndjolo, A; Nka, AD; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Teto, G; Tommo Tchouaket, MC; Yagai, B; Zoung-Kanyi Bissek, AC | 1 |
| Cassidy, T; Flowers, T; Goemaere, E; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Omar, Z; Sayed, K; Van Zyl, G; Zhao, Y | 1 |
| Akodu, J; Ambrose, A; Barber, TJ; Bowman, C; Flores, K; Hart, J; Hunter, A; Kanitkar, T; Simoes, P | 1 |
| Fukuda, A; Hongo, H; Kurosaki, E; Maeno, Y; Nagao, T; Sebata, A; Suzuki, M; Tofukuji, A; Watanabe, T | 1 |
| Buzón, L; de Los Santos, I; Díaz de Santiago, A; Dueñas, C; Egido, M; Ferreira, E; Gómez, J; Iglesias, A; Iribarren, JA; Martín, C; Morán, MÁ; Moreno, E; Pedrero, R; Pousada, G; Rodríguez, L; Sepulveda, MA; Troya, J | 1 |
| Aydın, Ö; Bektas, B; Cağ, Y; Ergen, P; Karadağ, FY; Keskin, H; Üçışık, AC | 1 |
| Evitt, LA; Grove, RA; Nanji, S; Okoli, C; Snedecor, SJ; van Wyk, J | 1 |
| Albendín Iglesias, H; Alejos, B; Díaz, A; Hernando, V; Jarrín, I; Moreno, S; Peraire, J; Pérez Elías, MJ; Rial-Crestelo, D; Suárez-García, I; Tiraboschi, J; Vera García, M; Viñuela, L | 1 |
| Buzón, L; De la Fuente, S; De Los Santos, I; Dueñas-Gutiérrez, C; Ferreira, E; Gómez, J; Iribarren, JA; Moran, MA; Moreno, E; Pedrero-Tomé, R; Pousada, G; Troya, J | 1 |
| Ban, JK; Bunko, A; de Wet, JJ; Eberg, M; Ling, J; McKimm, M; Verdier, G | 1 |
| Arribas, JR; Bernardino, JI; Busca, C; Cadiñanos, J; De Miguel, R; González-García, J; Martín-Carbonero, L; Micán, R; Montejano, R; Montes, ML; Palmier, E; Pérez-Valero, I; Ramos, L; Serrano, L; Valencia, E | 1 |
| Caldeira, DB; Camargo, M; de Lima, IB; Dias, D; Diaz, RS; Galinskas, J; Hunter, JR; Nassar, I; Schechter, M; Sucupira, MC | 1 |
| Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Ambrosioni, J; Berrocal, L; Blanco, JL; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; González-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Martínez-Serra, A; Torres, B | 1 |
| Ambe Chenwi, C; Billong, SC; Bouba, Y; Colizzi, V; Ebiama Lifanda, L; Efakika Gabisa, J; Fainguem, N; Flore Yimga, J; Fokam, J; Hadja, H; Halle, EG; Ka'e, AC; Kamgaing, N; Kembou, E; Kengni Ngueko, AM; Kesseng, D; Ketchaji, A; Mamgue Dzukam, FY; Moudourou, S; Nayang Mundo, RA; Ndiang Tetang, S; Ndjolo, A; Ndombo Koki, P; Ngoufack Jagni Semengue, E; Njom-Nlend, AE; Nka, AD; Nnomo Zam, MK; Pabo, W; Pamen, B; Perno, CF; Saounde Temgoua, E; Simo Kamgaing, R; Sosso, SM; Takou, D; Tangimpundu, C; Tommo Tchouaket, MC; Zoung-Kanyi Bissek, AC | 1 |
| Ait-Khaled, M; Górgolas Hernández-Mora, M; Kinder, C; Lutz, T; Moodley, R; Moore, R; Parry, CM; Podzamczer, D; Saggu, P; Underwood, M; van Wyk, J; Wang, R; Wright, J; Wynne, B | 1 |
| Abalat-Torrres, A; Arrieta-Aldea, I; Cañas-Ruano, E; Canepa, C; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Knobel, P; Marcos, A; Villar-García, J | 1 |
| Curran, A; Diaz-Brito, V; Domingo, P; Garcia, B; Imaz, A; Morenilla, S; Niubó, J; Peñafiel, J; Podzamczer, D; Scévola, S; Soriano, I; Tiraboschi, J; Verdejo, G | 1 |
| Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F; Sanfilippo, A; Tamburrini, E | 1 |
| Dominguez-Macias, M; Espinosa, N; Gutierrez-Valencia, A; Herrero, M; Lopez-Cortes, LE; Lopez-Cortes, LF; Lozano, C; Muñoz-Muela, E; Praena-Fernandez, JM; Roca-Oporto, C; Saborido-Alconchel, A; Serna-Gallego, A; Sotomayor, C; Trujillo-Rodriguez, M | 1 |
| Benfield, T; Gerstoft, J; Hove, JD; Knudsen, A; Møller, S; Pedersen, KBH; Siebner, HR | 1 |
| Ajeh, R; Beloumou, G; Bouba, NP; Cappelli, G; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa, S; Fokam, J; Kembou, E; Mbanya, D; Ndjolo, A; Perno, CF; Santoro, MM; Semengue, ENJ; Takou, D; Tala, V; Teto, G | 1 |
| Agostini, E; Cattelan, A; Gardin, S; Leoni, D; Mazzitelli, M; Mengato, D; Putaggio, C; Sasset, L; Scaglione, V; Trunfio, M; Vania, E | 1 |
| Collier, AC; Delle Fratte, R; Eguchi, M; Ho, RJY; Melvin, AJ; Perazzolo, S; Stephen, ZR; Xu, X | 1 |
| Mhembere, T; Stranix-Chibanda, L | 1 |
| Bansi-Matharu, L; Cambiano, V; Cowan, F; Ehrenkranz, P; Gilks, CF; Godfrey, C; Hargreaves, JR; Lundgren, JD; Phillips, AN; Revill, P; Rodger, A; Shahmanesh, M; Sibanda, E; Sikwese, K; Smith, J | 1 |
| Buteaue, J; Dos Santos, G; Duval, N; Francois, K; Geffrard, H; Giron, A; Inzaule, SC; Jordan, MR; Journel, I; Pierre, E; Sued, O; Van Onacker, JD | 1 |
| Kouamou, V; Manasa, J; Ndhlovu, CE; Washaya, T | 1 |
| Espinosa, A; Horta, AM; Lázaro, A; Mendoza, I; Sánchez, L; Torralba, M | 1 |
| Antinori, S; Borghi, V; Ciccullo, A; D'Ettorre, G; De Vito, A; Di Giambenedetto, S; Ducci, F; Giacomelli, A; Giacometti, A; Lagi, F; Madeddu, G; Mussini, C; Pincino, R; Sterrantino, G; Taramasso, L | 1 |
| Bellecave, P; d'Arminio Monforte, A; Egger, M; Gill, MJ; Günthard, HF; Hossmann, S; Ingle, SM; Kouyos, RD; Kusejko, K; Lessells, R; Loosli, T; Maartens, G; Mouton, J; Okhai, H; Sabin, CA; Stecher, M; Sterne, JAC; van Sighem, A | 1 |
| Ait-Khaled, M; Espinosa, N; Fernvik, E; Grove, R; Gulminetti, R; Hagins, D; Man, C; Sierra Madero, J; Sievers, J; Tsai, HC; van Wyk, J; Wynne, B; Zolopa, A | 1 |
| Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B | 1 |
| Deng, Y; He, L; Li, J; Wang, Y; Wei, Y; Wen, L; Xu, R; Zhong, H | 1 |
| Bertine, M; Cabié, A; Charpentier, C; Coppée, R; Descamps, D; Ghosn, J; Joly, V; Katlama, C; Landman, R; Mazouz, F; Peytavin, G; Raffi, F; Storto, A; Yazdanpanah, Y | 1 |
| Cheng, J; He, S; He, Y; Liu, H; Lu, C; Yang, T; Yao, Y; Yin, K; Zhou, R | 1 |
23 review(s) available for lamivudine and dolutegravir
| Article | Year |
|---|---|
Dolutegravir for the treatment of adult patients with HIV-1 infection.
Topics: Adult; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2014 |
Dolutegravir, abacavir and lamivudine as HIV therapy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Triumeq--a 3-drug combination for HIV.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Medication Adherence; Mutation; Oxazines; Piperazines; Practice Guidelines as Topic; Pyridones; Reverse Transcriptase Inhibitors; Tablets | 2015 |
[Safety profile of dolutegravir].
Topics: Bone Remodeling; Clinical Trials as Topic; Creatinine; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Drug Therapy, Combination; Gastrointestinal Diseases; Headache; Hepatitis, Viral, Human; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Immune Reconstitution Inflammatory Syndrome; Kidney Tubules; Lamivudine; Lipid Metabolism; Mood Disorders; Organic Cation Transport Proteins; Organic Cation Transporter 2; Oxazines; Piperazines; Pyridones; Respiration Disorders; Sleep Initiation and Maintenance Disorders | 2015 |
Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; RNA, Viral; Tablets | 2015 |
The preclinical discovery and development of dolutegravir for the treatment of HIV.
Topics: Animals; Dideoxynucleosides; Drug Combinations; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets | 2016 |
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Observational Studies as Topic; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine | 2018 |
Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.
Topics: Anti-HIV Agents; Drug Monitoring; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Residence Characteristics; Tenofovir; Viral Load | 2019 |
Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment.
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Equivalence Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; RNA, Viral; Viral Load | 2019 |
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Equivalence Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Sustained Virologic Response | 2020 |
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Failure | 2020 |
Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Drug Combinations; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets | 2020 |
Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2020 |
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Oxazines; Piperazines; Pyridones; Tablets; Treatment Outcome | 2020 |
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2022 |
An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; RNA; Tablets | 2023 |
55 trial(s) available for lamivudine and dolutegravir
| Article | Year |
|---|---|
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir | 2013 |
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Young Adult | 2013 |
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Dideoxynucleosides; Dietary Fats; Drug Combinations; Female; Food-Drug Interactions; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Therapeutic Equivalency; Vaginal Creams, Foams, and Jellies; Young Adult | 2014 |
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
Topics: Adult; Anti-HIV Agents; Cerebrospinal Fluid; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Plasma; Pyridones; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
Topics: Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir | 2016 |
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Interactions; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lactams, Macrocyclic; Lamivudine; Macrocyclic Compounds; Male; Middle Aged; Oxazines; Piperazines; Proline; Pyridones; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lipids; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Viral Load | 2017 |
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Topics: CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Canada; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Outcome; United States; Viral Load | 2017 |
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Pilot Projects; Piperazines; Pyridones; Viral Load | 2017 |
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pilot Projects; Piperazines; Pyridones | 2018 |
Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Viral Load | 2018 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Dideoxynucleosides; Drug Combinations; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Middle Aged; Minerals; Oxazines; Piperazines; Pyridones; Tablets; Water; Young Adult | 2018 |
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; DNA, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Viral Load; Young Adult | 2018 |
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Monitoring; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load; Young Adult | 2019 |
Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Topics: Adult; Anti-HIV Agents; Confidence Intervals; Dideoxynucleosides; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones | 2019 |
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Mutation; Oxazines; Pilot Projects; Piperazines; Pyridones; RNA, Viral; Treatment Failure; Viral Load; Young Adult | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Topics: Administration, Oral; Adult; Area Under Curve; Body Mass Index; Drug Therapy, Combination; Fasting; Female; Food; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Safety; Therapeutic Equivalency | 2020 |
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Topics: Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Young Adult | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Young Adult | 2020 |
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
Topics: Anti-HIV Agents; Chromatography, Liquid; Genitalia, Male; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Viral Load | 2020 |
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Pilot Projects; Piperazines; Pyridones; RNA, Viral; Viral Load | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pilot Projects; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2021 |
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Insulin Resistance; Lamivudine; Lipids; Metabolic Syndrome; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Weight Gain | 2021 |
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
Topics: Adult; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones | 2021 |
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Cholesterol, HDL; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2021 |
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome | 2022 |
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tablets; Young Adult | 2022 |
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Middle Aged; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, N
Topics: Adult; Anti-HIV Agents; Biomarkers; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; RNA, Viral | 2023 |
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Sexual and Gender Minorities; Viral Load | 2022 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Qualitative study exploring the experiences and perceptions of dolutegravir/lamivudine dual antiretroviral therapy (the PEDAL study) in people living with HIV: protocol.
Topics: Anti-HIV Agents; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Quality of Life | 2022 |
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load | 2022 |
Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Protease Inhibitors; Tenofovir; Viral Load; Young Adult; Zimbabwe | 2022 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir | 2023 |
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
Topics: Adult; Anti-Retroviral Agents; Argentina; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Transgender Persons | 2023 |
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic.
Topics: COVID-19; HIV Infections; Humans; Lamivudine; Pandemics; Retrospective Studies; Spain | 2023 |
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Isoniazid; Lamivudine; Rifampin; RNA; South Africa; Tenofovir; Tuberculosis; Viral Load | 2023 |
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Pyridones; RNA, Viral; Semen | 2023 |
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Male; Oxazines; Pyridones; RNA, Viral; Semen | 2023 |
Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open
Topics: Body Composition; Body Weight; Cardiovascular Diseases; Denmark; HIV Infections; Humans; Lamivudine; Quality of Life | 2023 |
150 other study(ies) available for lamivudine and dolutegravir
| Article | Year |
|---|---|
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Virus Replication | 2015 |
Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration.
Topics: Adolescent; Anti-HIV Agents; Black or African American; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Pancreatitis, Acute Necrotizing; Piperazines; Pyridones | 2015 |
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Models, Statistical; Oxazines; Piperazines; Pyridones; United States | 2016 |
A simultaneous determination of related substances by high performance liquid chromatography in a drug product using quality by design approach.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; Lamivudine; Monte Carlo Method; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Temperature | 2016 |
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2016 |
Single-tablet antiretroviral treatment (once daily).
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Drug Interactions; Drug Resistance, Viral; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Mental Disorders; Oxazines; Piperazines; Pyridones; Viral Load | 2016 |
A severe hypersensitivity reaction to abacavir following re-challenge.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; HLA-B Antigens; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2017 |
HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Piperazines; Plasma; Prospective Studies; Pyridones; RNA Stability; RNA, Viral; Semen; Time Factors; Young Adult | 2016 |
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir | 2017 |
A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy.
Topics: Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Disease Models, Animal; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-2; Humans; Lamivudine; Mice; Mice, Inbred BALB C; Oxazines; Piperazines; Pyridones | 2017 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Topics: Adult; Aged; Aged, 80 and over; Cobicistat; Dideoxynucleosides; Drug Combinations; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; Risk Factors; Spain; Treatment Outcome; Young Adult | 2017 |
Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
Topics: Adult; Algorithms; Anti-HIV Agents; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; France; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Markov Chains; Oxazines; Piperazines; Practice Guidelines as Topic; Pyridones; Quality-Adjusted Life Years; Treatment Outcome | 2018 |
Severe depression as a neuropsychiatric side effect induced by dolutegravir.
Topics: Depression; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Withholding Treatment | 2018 |
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2017 |
Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; Drug Compounding; Female; Heterocyclic Compounds, 3-Ring; HIV Seropositivity; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Spain | 2017 |
A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.
Topics: Anti-HIV Agents; Australia; Clinical Audit; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; General Practice; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Motivation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Sustained Virologic Response; Treatment Outcome | 2018 |
HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genome, Viral; Genotype; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Oxazines; Pilot Projects; Piperazines; Pyridones | 2017 |
Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters.
Topics: Adolescent; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Hospitals, Pediatric; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Referral and Consultation; Spain; Tablets | 2017 |
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Pilot Projects; Piperazines; Pyridones; RNA, Viral; Viral Load | 2018 |
Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.
Topics: Adult; Anti-Retroviral Agents; Canada; Cohort Studies; Cost Savings; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Piperazines; Practice Patterns, Physicians'; Pyridones; Tablets | 2018 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Photoallergic dermatitis associated with fixed-dose combination of antiretroviral agent (abacavir-lamivudine-dolutegravir).
Topics: Adult; Anti-Retroviral Agents; Dermatitis, Photoallergic; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Skin | 2018 |
Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cholestasis; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2018 |
Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression.
Topics: Adenocarcinoma; Anti-Retroviral Agents; Dideoxynucleosides; Gastric Outlet Obstruction; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Intubation, Gastrointestinal; Lamivudine; Male; Middle Aged; Oxazines; Parenteral Nutrition; Piperazines; Pyridones; Stomach Neoplasms; Sustained Virologic Response; Treatment Outcome | 2019 |
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rilpivirine; Viral Load | 2019 |
Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Quality-Adjusted Life Years; Raltegravir Potassium; Russia | 2018 |
Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Substitution; Drugs, Generic; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2018 |
Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Renal Dialysis; Tablets; Treatment Outcome; Viral Load | 2019 |
Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.
Topics: Anti-HIV Agents; Female; Genitalia; Genotyping Techniques; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Outcome; Virus Shedding | 2018 |
A two-drug regimen for antiretroviral therapy.
Topics: Adult; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.
Topics: Anti-HIV Agents; Bone Density; Drug Combinations; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies | 2018 |
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Interactions; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Pilot Projects; Piperazines; Prospective Studies; Pyridones; Time Factors; Viral Load | 2019 |
Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives?
Topics: Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine | 2019 |
Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Calcium; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Hypocalcemia; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prevalence; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Studies as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Capillary Permeability; Corpus Striatum; Dextrans; Dideoxynucleosides; Female; Fluorescein-5-isothiocyanate; Heterocyclic Compounds, 3-Ring; Hippocampus; HIV Infections; HIV-1; Lamivudine; Mice; Mice, Transgenic; Models, Biological; Morphine; Neurocognitive Disorders; Oxazines; Piperazines; Pyridones; tat Gene Products, Human Immunodeficiency Virus | 2019 |
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.
Topics: Adolescent; Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Cohort Studies; Dideoxynucleosides; Disease Progression; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Young Adult | 2019 |
Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Treatment Outcome; Viral Load | 2019 |
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
Topics: Adolescent; Cross-Sectional Studies; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Failure; Viral Load; Young Adult; Zimbabwe | 2019 |
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Fees, Pharmaceutical; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2019 |
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Practice Patterns, Physicians'; Preliminary Data; Pyridones; RNA, Viral; Sustained Virologic Response | 2020 |
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Topics: Aged; Aged, 80 and over; Aging; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Viral Load | 2020 |
Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Illinois; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prisoners; Prisons; Pyridones; Retrospective Studies; Treatment Outcome | 2019 |
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Genes, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load | 2019 |
HIV 101: fundamentals of antiretroviral therapy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Drug updates and approvals: 2019 in review.
Topics: Antibodies, Monoclonal; Azetidines; Benzyl Compounds; beta-Cyclodextrins; Carbamates; Clobetasol; Drug Approval; Drug Combinations; Formoterol Fumarate; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Nicotinic Acids; Oxazines; Phenylalanine; Piperazines; Pregnanolone; Pyridones; Tropanes; United States; United States Food and Drug Administration | 2019 |
Simplified two-drug antiretroviral HIV treatment: novel data and expected impact.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Piperazines; Pyridones; RNA Stability; RNA, Viral; Sexual and Gender Minorities; Viral Load | 2020 |
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Italy; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rilpivirine; Treatment Outcome | 2019 |
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tablets; Treatment Outcome | 2019 |
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2020 |
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome | 2020 |
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report.
Topics: DNA; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Mutation; Oxazines; Piperazines; Preliminary Data; Pyridones | 2020 |
Kaposi's sarcoma in a HIV-positive patient: an exuberant and widespread case report in the Amazon.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir | 2020 |
Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
Topics: Adult; Anti-Retroviral Agents; Bariatric Surgery; Dideoxynucleosides; Drug Monitoring; Gastrectomy; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Obesity, Morbid; Oxazines; Piperazines; Pyridones | 2020 |
Lamivudine-resistant HIV
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Mice; Mutation; Oxazines; Piperazines; Pyridones; Treatment Outcome | 2020 |
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
Topics: Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2020 |
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
Topics: Anti-HIV Agents; DNA; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Viral Load | 2020 |
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir.
Topics: Adipose Tissue; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Weight Gain | 2020 |
Monitoring the transition to new antiretroviral treatment regimens through an enhanced data system in Kenya.
Topics: Anti-HIV Agents; Data Systems; Database Management Systems; Drug Monitoring; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Extracorporeal Membrane Oxygenation; Female; Heart-Lung Transplantation; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Intubation, Gastrointestinal; Lamivudine; Oxazines; Piperazines; Pyridones | 2020 |
Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
Topics: Anti-HIV Agents; Genotype; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2020 |
Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Rilpivirine | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones | 2020 |
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Retrospective Studies; Viral Load | 2020 |
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Topics: Adult; Female; Government Programs; Health Facilities; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pregnancy; Pyridones; Qualitative Research; South Africa; Tenofovir; Uganda | 2020 |
Recurrent ocular syphilis in a patient living with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Dideoxynucleosides; Eye Infections, Bacterial; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Neurosyphilis; Oxazines; Penicillin G; Piperazines; Pyridones; Syphilis; Syphilis Serodiagnosis; Treatment Outcome; Treponema pallidum; Uveitis; Visual Acuity | 2020 |
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
Topics: Age Factors; Anti-Retroviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome; Triazoles | 2020 |
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
Topics: Adult; Anti-HIV Agents; DNA; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones | 2020 |
No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62).
Topics: Anti-HIV Agents; Biomarkers; Drug Substitution; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Viral Load | 2021 |
Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir.
Topics: Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin; Lamivudine; Menopause; Nitriles; Oxazines; Piperazines; Pyridones; Pyrimidines; Raltegravir Potassium; Waist Circumference; Weight Gain | 2021 |
Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors | 2021 |
Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza
Topics: Adipose Tissue; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium | 2021 |
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; South Africa; Tenofovir; Viral Load | 2021 |
Box-Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co-loaded in nano-liposomes.
Topics: Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Carriers; Drug Compounding; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Lamivudine; Limit of Detection; Liposomes; Nanoparticles; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors | 2021 |
Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Body Weight; Cohort Studies; Dideoxynucleosides; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Heart Disease Risk Factors; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Italy; Lamivudine; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tablets | 2021 |
Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2021 |
Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Spain; Tablets | 2021 |
Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Viral Load | 2022 |
Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets | 2021 |
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; RNA | 2021 |
Analysis of the ternary antiretroviral therapy dolutegravir, lamivudine and abacavir using UV spectrophotometry and chemometric tools.
Topics: Calibration; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Least-Squares Analysis; Oxazines; Piperazines; Pyridones; Spectrophotometry; Spectrophotometry, Ultraviolet | 2022 |
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Topics: Anti-HIV Agents; Cobicistat; Creatinine; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine | 2023 |
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Rilpivirine; Viral Load | 2021 |
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
Topics: Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2022 |
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.
Topics: Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies | 2022 |
Development and validation of ultra performance liquid chromatography-tandem mass spectrometry method for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Heterocyclic Compounds, 3-Ring; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets; Tandem Mass Spectrometry; Tenofovir | 2021 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kenya; Lamivudine; Oxazines; Peptide Hydrolases; Piperazines; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Tenofovir | 2022 |
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
Topics: Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Mutation; Oxazines; Piperazines; Pyridones; Rilpivirine | 2022 |
Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
Topics: Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Integrases; Lamivudine; Leukocytes, Mononuclear; Male; Oxazines; Piperazines; Pyridones; RNA-Directed DNA Polymerase; Viremia | 2022 |
Weight gain during the dolutegravir transition in the African Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Topics: Adult; Amides; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cohort Studies; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2022 |
Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Surface Antigens; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; RNA; RNA, Viral; Viral Load | 2022 |
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lesotho; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Prospective Studies; Self Report; Tenofovir | 2023 |
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2022 |
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Malawi; Oxazines; Piperazines; Prospective Studies; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2022 |
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Topics: Anti-HIV Agents; Belgium; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Rilpivirine; Treatment Outcome | 2023 |
Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Preliminary Data; Prospective Studies; Pyridones; Retrospective Studies; RNA, Viral; Viral Load | 2022 |
Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Observ
Topics: Adult; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir | 2022 |
Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Sexual and Gender Minorities | 2022 |
Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Viral Load | 2022 |
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Topics: Anti-HIV Agents; Antigens, Surface; Creatinine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; RNA; Viral Load | 2022 |
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Rilpivirine | 2022 |
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Creatinine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Prospective Studies; Pyridones; RNA; Tenofovir; Triglycerides | 2022 |
HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report.
Topics: Drug Resistance, Viral; HIV Integrase; HIV-1; Humans; Lamivudine; Retrospective Studies; Treatment Adherence and Compliance | 2022 |
Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China: Erratum.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pyridones | 2022 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Oxazines; Retrospective Studies | 2023 |
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.
Topics: Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Retrospective Studies; RNA; Viral Load | 2023 |
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; COVID-19; HIV Infections; HIV-1; Humans; Lamivudine; Pandemics | 2022 |
Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Lamivudine; Republic of Korea; Retrospective Studies | 2022 |
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Cameroon; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load | 2022 |
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Viral Load; Viremia | 2023 |
Real world use of dolutegravir two drug regimens.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Pyridones; Sexual and Gender Minorities; Tablets; Viremia | 2023 |
Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan.
Topics: Anti-HIV Agents; HIV Infections; Humans; Japan; Lamivudine; Oxazines; Product Surveillance, Postmarketing; Pyridones; RNA | 2023 |
Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Retrospective Studies; Treatment Outcome | 2022 |
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pyridones | 2023 |
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Retrospective Studies; Rilpivirine | 2023 |
A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine.
Topics: Anti-HIV Agents; Canada; HIV Infections; Humans; Lamivudine; Nevirapine; Oxazines; Patient Acceptance of Health Care; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2023 |
Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA | 2023 |
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.
Topics: Anti-Retroviral Agents; Brazil; HIV Infections; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Retrospective Studies | 2023 |
Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Lamivudine; Male; Pediatrics; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2023 |
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2023 |
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.
Topics: Adenine; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Retrospective Studies; Treatment Outcome | 2023 |
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Prospective Studies; Pyridones; Telomere; Viral Load | 2023 |
Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens.
Topics: Cameroon; HIV Seropositivity; HIV-1; Humans; Lamivudine; Tenofovir | 2023 |
Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV.
Topics: Aged; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Silver | 2023 |
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
Topics: Animals; Anti-HIV Agents; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Lamivudine; Leukocytes, Mononuclear; Oxazines; Pharmaceutical Preparations; Pyridones; Tenofovir | 2023 |
Unrestricted access to tenofovir, lamivudine, and dolutegravir as pre-exposure or post-exposure prophylaxis in community settings.
Topics: Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Post-Exposure Prophylaxis; Tenofovir | 2023 |
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
Topics: Africa, Western; Cost-Benefit Analysis; Female; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2023 |
First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Lamivudine; Mothers; Oxazines; Pregnancy; Tenofovir | 2023 |
Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
Topics: Adult; Humans; Lamivudine; Prevalence; Prospective Studies; Tenofovir; Zimbabwe | 2023 |
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones | 2023 |
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
Topics: Cohort Studies; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2023 |
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Tenofovir; Treatment Adherence and Compliance | 2023 |
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir | 2023 |
Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Topics: Adult; Anti-HIV Agents; China; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Retrospective Studies | 2023 |
Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.
Topics: Anti-HIV Agents; APOBEC Deaminases; DNA; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Pyridones; Viral Load | 2023 |
Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Middle Aged; Peptides; Pyridones; Retrospective Studies; Viral Load | 2023 |